This article is more than 5 years old. Information may no longer be current.
Medtronic receives FDA approval for spinal cord simulator to manage chronic pain
Click Here to Manage Email Alerts
Medtronic recently announced the FDA approval and U.S. launch of the Intellis platform for the management of chronic intractable pain.
According to a company press release, the device can track patient activity and is programmed on the Samsung Galaxy Tab S2 tablet interface. The stimulator allows physicians to address chronic pain by monitoring progress and making changes to accommodate patients’ therapy needs.
“Drawing upon our 40-year legacy in [spinal cord stimulation] SCS, the launch of the Intellis platform is not just about a new device, but about combining cutting-edge hardware with optimal therapy through the Evolve workflow to enable personalized, long-term pain relief,” Marshall Stanton, MD, senior vice president and president of Medtronic’s Pain Therapies Division, said in the release. “Medtronic is committed to addressing patient needs, so the Intellis platform was designed based on what is most important to patients and physicians. We considered the entire patient journey — starting with the primary goal of optimal pain relief and access to important diagnostic tools, like MRI, to ease of use with simplified programming, faster recharge and a smaller implant.”
Reference: